Shripada Rao1, Ravisha Srinivasjois, Sanjay Patole. 1. Department of Neonatal Pediatrics, Princess Margaret Hospital for Children, Roberts Road, Subiaco, Perth, Western Australia 6008, Australia. Shripada.Rao@health.wa.gov.au
Abstract
OBJECTIVE: To systematically review randomized controlled trials evaluating the efficacy and safety of prebiotic supplementation in full-term neonates. DATA SOURCES: Cochrane Central Register of Controlled Trials, MEDLINE, EMBASE, and CINAHL databases and proceedings of relevant conferences. STUDY SELECTION: Eleven of 24 identified trials (n = 1459) were eligible for inclusion. Intervention Trials comparing formula milk supplemented with or without prebiotics, commenced at or before age 28 days and continued for 2 weeks or longer. MAIN OUTCOME MEASURES: Stool colony counts (bifidobacteria, lactobacilli, and pathogens), pH, consistency, frequency, anthropometry, and symptoms of intolerance. RESULTS: Six trials reported significant increases and 2 reported a trend toward increases in bifidobacteria counts after supplementation. Meta-analysis estimated significant reduction in stool pH in infants who received prebiotic supplementation (weighted mean difference, -0.65; 95% confidence interval, -0.76 to -0.54; 6 trials). Infants who receive a supplement had slightly better weight gain than did controls (weighted mean difference, 1.07 g; 95% confidence interval, 0.14-1.99; 4 trials) with softer and frequent stools similar to breastfed infants. All but 1 trial reported that prebiotic supplementation was well tolerated. In that trial, diarrhea (18% vs 4%; P = .008), irritability (16% vs 4%; P = .03), and eczema (18% vs 7%; P = .046) were reported more frequently by parents of infants who received prebiotic supplements. CONCLUSIONS: Prebiotic-supplemented formula is well tolerated by full-term infants. It increases stool colony counts of bifidobacteria and lactobacilli and results in stools similar to those of breastfed neonates without affecting weight gain. Larger trials with long-term follow-up are needed to determine whether these short-term benefits are sustained.
OBJECTIVE: To systematically review randomized controlled trials evaluating the efficacy and safety of prebiotic supplementation in full-term neonates. DATA SOURCES: Cochrane Central Register of Controlled Trials, MEDLINE, EMBASE, and CINAHL databases and proceedings of relevant conferences. STUDY SELECTION: Eleven of 24 identified trials (n = 1459) were eligible for inclusion. Intervention Trials comparing formula milk supplemented with or without prebiotics, commenced at or before age 28 days and continued for 2 weeks or longer. MAIN OUTCOME MEASURES: Stool colony counts (bifidobacteria, lactobacilli, and pathogens), pH, consistency, frequency, anthropometry, and symptoms of intolerance. RESULTS: Six trials reported significant increases and 2 reported a trend toward increases in bifidobacteria counts after supplementation. Meta-analysis estimated significant reduction in stool pH in infants who received prebiotic supplementation (weighted mean difference, -0.65; 95% confidence interval, -0.76 to -0.54; 6 trials). Infants who receive a supplement had slightly better weight gain than did controls (weighted mean difference, 1.07 g; 95% confidence interval, 0.14-1.99; 4 trials) with softer and frequent stools similar to breastfed infants. All but 1 trial reported that prebiotic supplementation was well tolerated. In that trial, diarrhea (18% vs 4%; P = .008), irritability (16% vs 4%; P = .03), and eczema (18% vs 7%; P = .046) were reported more frequently by parents of infants who received prebiotic supplements. CONCLUSIONS: Prebiotic-supplemented formula is well tolerated by full-term infants. It increases stool colony counts of bifidobacteria and lactobacilli and results in stools similar to those of breastfed neonates without affecting weight gain. Larger trials with long-term follow-up are needed to determine whether these short-term benefits are sustained.
Authors: J Stiverson; T Williams; J Chen; S Adams; D Hustead; P Price; J Guerrieri; J Deacon; Z Yu Journal: Appl Environ Microbiol Date: 2014-09-19 Impact factor: 4.792
Authors: Madhu S Malo; Omeed Moaven; Nur Muhammad; Brishti Biswas; Sayeda N Alam; Konstantinos P Economopoulos; Sarah Shireen Gul; Sulaiman R Hamarneh; Nondita S Malo; Abeba Teshager; Mussa M Rafat Mohamed; Qingsong Tao; Sonoko Narisawa; José Luis Millán; Elizabeth L Hohmann; H Shaw Warren; Simon C Robson; Richard A Hodin Journal: Am J Physiol Gastrointest Liver Physiol Date: 2014-04-10 Impact factor: 4.052